Natacha Bolaños

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap

Eliza A. Hawkes, Eliza Chung, Mark Bishton, Natacha Bolaños et autres

Lymphomas comprise a complex and heterogeneous group of malignancies which pose challenges in understanding their epidemiology, pathobiology, treatment responses and long-term outcomes. Evolving diagnostic classification and fast-paced therapy development compound these challenges. Robust real-world data (RWD) collection and analysis using clinical registries …

au, gb, fr, us, it, de, sg, se, ca, nl, ar, cz, dk (code pays fourni par la source)

The European CAR‐T map—Current status and future directions to improve access to CAR T‐cell therapy for hematologic malignancies

Elise R. A. Pennings, Frederick W. Thielen, Florence Broussais, Julio Delgado et autres

Despite its great promise, implementation of CAR-T therapy-a personalized, logistically complex, and expensive treatment-remains challenging, hampering patient access across and within countries. Since 2018, six products have been centrally approved in Europe (i.e., the European Economic Area; EU-approved) for 15 hematologic malignancy …

fr, nl, es, at, de, us, be, cz (code pays fourni par la source)

Reduce bureaucracy in clinical trials now

Martin Dreyling, Sara Badreh Wirström, Wolfgang E. Berdel, Natacha Bolaños et autres

de, nl, us, gb, dk, pt, br, fr, hr, ch, be (code pays fourni par la source)

Challenging the Status Quo on Lymphoma Research Endpoints: Results from a Global Stakeholder Survey

Natacha Bolaños, Florence Broussais, Judith Trotman, Eliza Hawkes et autres

fr, au, us (code pays fourni par la source)

Evolving patient-reported value of treatment attributes in follicular lymphoma: Insights from the lymphoma coalition 2024 global patient survey on lymphomas and CLL

Natacha Bolaños, Mavis Lui, Lorna Warwick

Abstract Background Follicular lymphoma (FL) is a chronic, indolent lymphoma, characterized by a typically slow-growing but incurable disease course, with repeated cycles of active monitoring, and treatment. Initial treatment often achieves durable responses; however, many patients experience disease recurrence and multiple lines …

us (code pays fourni par la source)

Variances in patient reported experiences with shared decision-making by biological sex in patients with diffuse large B-cell lymphoma (DLBCL) – an analysis from the lymphoma coalition 2024 global patient survey on lymphomas and CLL

Lorna Warwick, Shawn Sajkowski, Natacha Bolaños

Abstract Introduction Shared decision-making (SDM) remains a key aspect of the patient-centred care paradigm in patients with lymphomas and CLL. It involves not only patient inclusion in key decisions regarding their care but also requires healthcare providers (HCP) to understand the preferences …

us (code pays fourni par la source)

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

Elise R. A. Pennings, Anne M. Spanjaart, Frederick W. Thielen, Simone Oerlemans et autres

ABSTRACT: Patient-reported outcomes (PROs) give direct insights into the treatment's impact on patient's life and complement clinical outcomes. However, since the advent of chimeric antigen receptor T-cell therapy (CAR-T), PROs have been underreported. Particularly, little is known about long-term health-related quality of …

nl, us, de, pt, fr, at, es, lu, be, gb, ca, it (code pays fourni par la source)

Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up

Catherine Thiéblemont, María Gomes da Silva, Sirpa Leppä, Georg Lenz et autres

rearrangements indicate a poor prognosis. Staging and prognosis rely on positron emission tomography computed tomography (PET-CT). The International Prognostic Index (IPI) aids risk stratification. PET-CT is critical for assessing treatment response and guiding strategies. First-line management for LBCL can be informed by …

fr, pt, fi, de, gb, es, hu, hr, cz, nl, it (code pays fourni par la source)

Bridging gaps in clinical trial accessibility and reimbursement for large B‐cell lymphoma therapies across Europe

Florence Broussais, Elise R. A. Pennings, Natacha Bolaños, Lorna Warwick et autres

Peer reviewed

fr, nl, pt, fi, de, gb, es, hu, hr, cz, it (code pays fourni par la source)

HSR25-164: Mapping Patient Reported Side-Effect Incidence to Degradation of Health-Related Quality of Life Dimensions in Lymphoma and Chronic Lymphocytic Leukemia – A Study From the Lymphoma Coalition’s 2024 Global Patient Survey on Lymphomas & CLL

Steve E. Kalloger, Amanda Watson, Shawn Sajkowski, Natacha Bolaños et autres

"HSR25-164: Mapping Patient Reported Side-Effect Incidence to Degradation of Health-Related Quality of Life Dimensions in Lymphoma and Chronic Lymphocytic Leukemia – A Study From the Lymphoma Coalition’s 2024 Global Patient Survey on Lymphomas & CLL" published on 28 Mar 2025 by National …

ca (code pays fourni par la source)

Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe

Hélène Schoemans, Elke Stienissen, Kathy Goris, Susan K. Stewart et autres

be, us, at, nl, pt, fr, sk, ca, de (code pays fourni par la source)

Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet

Vincent Ribrag, Dominique Bron, Grzegorz Rymkiewicz, Dieter Hoelzer et autres

fr, be, hu, de, dk, es, it, us, nl (code pays fourni par la source)